Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility were there are wide-spread medical needs.

Further reading »

Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »

The Share

Latest News

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

August 31 2015
The shareholders of Oasmia Pharmaceutical AB (publ), 556332-6676, are invited to participate in the Annual General Meeting to be held on Monday, September 28, 2015 at 2 p.m. at Vallongatan 1, Uppsala, Sweden. The registration will start at 1.30 p.m.
Further reading »

The Oasmia Pharmaceutiacal Annual Report is now published

August 21 2015
Further reading »

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow

August 17 2015
New York, August 17, 2015 -- Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission to include final full-year financials in connection with its proposed public offering of American Depositary Shares representing its Ordinary Shares and contemporaneous listing of the American Depositary Shares on the US Nasdaq Capital Market.
Further reading »